#Vosevi

There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.

Treatment for hep C has improved greatly over the past decades, with medications that treat more than one virus strain at the same time.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.

In a recent study of people whose previous hep C regimen failed to cure their infection, Vosevi cured almost all of them.

Ninety-seven percent of those who took the Gilead regimen after failing a previous therapy were cured in a recent study.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC

Having hepatitis C with evidence of resistance to medications did not impact the chances of a cure in a recent study.